Drugs
FDA has cleared a Camber Spine Technologies 510(k) for the SPIRA Open Matrix ALIF device, an interbody fusion implant consisting of spiral support arches and the company’s “Surface by Design” technology.“The spiral support arches decrease subsidence by load sharing over the entire endplate, while also maximizing bone
FDA Policy/General
Federal Register notice: FDA is seeking comments on a proposed method for applying a food animal biomass denominator to annual data on antimicrobials sold and distributed for use in food animals in the U.S. The method will allow the agency to obtain a corrected estimate of antimicrobial drug sales
FDA Policy/General
A new policy on security background checks is raising confusion and alarm for some FDA scientists, according to an online Science post. The article says the change was included in a “communications plan” that went to agency senior staff in recent weeks. Science says the plan “appears to effectively bar
Drugs
Teva and its Barr Laboratories and Watson Laboratories subsidiaries are asking the DC federal court for permission to intervene in Amgen’s suit against FDA over the agency’s refusal to grant the company pediatric exclusivity for its Sensipar (cinacalcet hydrochloride). The generic companies argue that Amgen’s suit, which
Devices
Medtronic says it will conduct a randomized clinical to evaluate one-month dual antiplatelet therapy (DAPT) — the combination of aspirin and an anti-clotting medication — in patients implanted with the Resolute Onyx Drug-Eluting Stent (DES) during percutaneous coronary intervention. The study is intended to help provide DAPT guidelines for
FDA Policy/General
Federal Register notice: FDA is requesting comments about abuse potential, actual abuse, medical usefulness, trafficking, and impact of scheduling changes on availability for medical use of 17 drug substances. The comments will be considered in preparing a response from the U.S. to the World Health Organization (WHO) regarding abuse
Drugs
Lipocine has resubmitted an NDA for Tlando, an oral testosterone product candidate for testosterone replacement therapy in adult males for conditions associated with a deficiency of endogenous testosterone (hypogonadism). The resubmission addresses issues outlined in a 6/2016 complete response letter and provides additional information related to the dosing algorithm
Drugs
International Laboratories has recalled one lot of pravastatin sodium tablets USP 40 mg packaged in bottles of 30 tablets due to mislabeling. The product is labeled as pravastatin sodium but the lot contained bupropion hydrochloride 300 mg tablets. “If a subject mistakenly takes bupropion, common side effects include: nausea, vomiting,
Drugs
President Trump lashed out at Merck CEO Kenneth Frazier after he resigned 8/14 from the president’s American Manufacturing Council in protest against “intolerance and extremism” in the wake of demonstrations and clashes in Charlottesville, VA. Frazier, who is black, was invited to the White House early after the
FDA Policy/General
FDA’s Center for Veterinary Medicine is proposing to use a “biomass indicator” to help it better analyze antimicrobial sales and food-animal population data it already receives. According to an 8/14 CVM Update, a biomass denominator is the population of a given livestock population in the U.S.
Drugs
FDA has lifted a clinical hold against CEL-SCI Corp. and its Phase 3 cancer study with Multikine (leukocyte interleukin, injection), allowing all clinical trial activities under the company’s IND to resume. In June, CEL-SCI responded to FDA about the clinical hold on the Phase 3 head and
Drugs
FDA has told Reata Pharmaceuticals that its modified Friedreich’s Ataxia Rating Scale (mFARS) is an acceptable primary endpoint for Part 2 of the company’s MOXIe trial for omaveloxolone in Friedreich’s ataxia (FA). The rare, degenerative, life-shortening neuro-muscular disorder affects children and adults and involves the
Drugs
Guidance on Medical Device Development Tools Federal Register notice: FDA announces the availability of a guidance on “Qualification of Medical Device Development Tools (MDDT)” that is intended to finalize the MDDT program. 08/10/2017 Guide on Expiry Dating for Unit Dose Repackaging Federal Register notice: FDA announces the availability
Drugs
FDA and Chiasma have reached agreement on a special protocol assessment on the design of a new Phase 3 clinical trial for its octreotide capsules product candidate for the maintenance therapy of adult patients with acromegaly. The study is designed to address agency concerns raised in a previously issued complete
Drugs
FDA has granted Gilead Sciences a priority review for its NDA for an investigational, fixed-dose combination of bictegravir (50mg), an integrase strand transfer inhibitor, and emtricitabine/tenofovir alafenamide (200/25mg), a dual-NRTI backbone, for treating HIV-1 infection. Gilead filed the NDA with a priority review voucher on
Drugs
President Donald Trump says he is declaring the opioid epidemic a national emergency, adding that his administration is drafting paperwork to make it official. The move follows a main recommendation in a 7/31 White House-commissioned interim report that was directed by governor Chris Christie. A final report will
Devices
FDA has cleared a Renovis Surgical Technologies 510(k) to market posterior lumbar Tesera porous titanium interbody fusion systems. The device line features implants for direct posterior or transforaminal approaches in both straight and curved options, according to the company. Multiple heights, widths and lengths are available to better fit
Drugs
FDA has granted Anthera Pharmaceuticals an orphan drug designation for blisibimod for treating immunoglobulin A nephropathy (IgAN). The company says that blisibimod targets B-cell activating factor, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including IgAN, systemic lupus erythematosus, and others.
Drugs
TherapeuticsMD says it will submit additional endometrial safety information to address the only approvability issue raised in a May-issued complete response letter (CRL) on an NDA for TX-004HR, the company’s investigational applicator-free estradiol vaginal softgel capsule for treating moderate-to-severe vaginal pain during sexual intercourse
Drugs
FDA has posted a guide for physicians seeking to submit requests for non-emergency single-patient expanded access to investigational therapies. According to the guide, such requests begin with a physician obtaining a Letter of Authorization (LOA) from the pharmaceutical company that makes the investigational drug. “A LOA grants the
FDA Policy/General
Federal Register notice: FDA has announced the availability of a guidance on “Qualification of Medical Device Development Tools (MDDT)” that is intended to finalize the MDDT program. The document also discusses the framework of an MDDT, including definitions of applicable terms, criteria for evaluating an MDDT for a specific context
Devices
CDRH has released frequently asked questions (FAQs) about the new medical device pre-certification pilot program. The document covers 13 questions about eligibility for the program and how it will operate.